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Objectives.W ee v a l u a t e dt h ee ﬃcacy of magnesium sulfate as a second-line tocolysis for 48hours. Materials and Methods.Amu lt i-
institutional, simple 2-arm randomized controlled trial was performed. Forty-ﬁve women at 22 to 34 weeks of gestation were
eligible, whoseritodrine did notsuﬃcientlyinhibituterine contractions.After excluding 12women,33 were randomlyassignedto
either magnesium alone or combination (ritodrine and magnesium). The treatment was determined as eﬀective if the frequency
of uterine contraction wasreduced by 30% at 48hours ofthe treatment. Results. After magnesiumsulfate infusion,90% prolonged
their pregnancy for >48hours. Combination therapy was eﬀective in 95% (18/19), which was signiﬁcantly higher than 50%
(7/14) for magnesium alone. Conclusion. This randomized trial revealed that combination therapy signiﬁcantly reduced uterine
contractions, suggesting that adjuvant magnesium with ritodrine is recommended, rather than changing into magnesium alone,
when uterine contractions are intractable with ritodrine infusion.
1.Introduction
Acute tocolysis prevents preterm labor for 48 hours, which
is the critical period for antenatal steroid administration or
maternal transfer to perinatal centers to improve neonatal
outcomes. Evidence supporting the eﬀectiveness of magne-
siumsulfatefortocolysisiscurrentlybeingquestioned.Meta-
analysis comparing magnesium sulfate and either placebo,
no treatment, or alternative tocolytic agents showed that
magnesium reduces the risk of birth within 48 hours by
15%, which is not statistically signiﬁcant (relative risk (RR)
0.85, 95% conﬁdence interval (CI) 0.58 to 1.25) [1]. A more
recent report evaluating 19 randomized controlled trials
revealsthat magnesium fails toreduce deliveryrate within 48
hours [2]. However, magnesium sulfate is currently the most
commonly used tocolytic agent in America.
In 2008, the Ministry of Health, Labor and Welfare
of Japan ﬁnally approved magnesium sulfate as a tocolytic
agent, but its use is restricted to the second-line tocolysis
when the eﬀect of a betamimetic agonist is not suﬃcient to
reduceuterinecontractions. Here,aquestionarises as tohow
we administer magnesium sulfate to these women, that is,
to stop the betamimetic agonist and change into magnesium
sulfate oradd magnesium sulfate to the betamimetic agonist.
The eﬃcacy of tocolysis when using a combination of
a betamimetic agonist and magnesium sulfate has been
investigated, and some retrospective studies have shown
that a combination therapy may be eﬀective in prolonging
gestation [3–7]. On the other hand, a prospective random-
ized study showed that such treatment may not improve
tocolytic eﬃcacy [8] but produced an unacceptable increase
in serious maternal side eﬀe c t s .A tp r e s e n t ,t h e r ea r en o
randomizedcontrolledtrialscomparingthe2modesofusing
magnesium sulfate, either change or addition, as a second-
line tocolytic agent in cases where a betamimetic agonist
alone is not suﬃcient to inhibit preterm labor. Since the
mechanisms of tocolytic action diﬀer between magnesium
sulfate and betamimetics, we hypothesized that adding2 Journal of Pregnancy
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Figure 1: Flowchart of a simple 2-arm randomized controlled trial.
magnesium sulfate to the treatment would be superior to
using magnesium sulfate alone for the inhibition of uterine
contractions. We tested this hypothesis in a prospective,
randomized controlled trial.
2.Materialsand Methods
This study was approved by the institutional review board of
the University of Miyazaki and all the participating institu-
tions. A multi-institutional, prospectively randomized trial
was performed from April 2007 to March 2009. We collected
data from 14 institutions: 3 were university hospitals and the
remaining 11 were regional referral centersin Kyushu,Japan.
Informed consent was obtained in each institution.
Inclusion criteria were singleton or dichorionic twin
pregnancies with intact membranes, showing clinical signs
of preterm labor at 22 to 34 weeks of gestation. The
starting point of 22 weeks of gestation was chosen because
their survival rate surpasses more than 50% in Japan, and
they are legally protected for the chance of survival in
Japan. Deﬁnition of preterm labor in Japan is diﬀerent
from that of others, that is, as the presence of sensitive
uterine contractions (6/hour or more) with the dura-
tion of >30 seconds, and changes in cervical dilation or
cervical length are not taken into consideration. Dating
of pregnancy was conﬁrmed by ﬁrst-trimester ultrasound
fetometry.
Exclusions were women with clinical intrauterine infec-
tion,abruption,cervicaldilatation>5cm, medicalcomplica-
tions contraindicating tocolysis, and evidence of nonreassur-
ing fetal status. Clinical intrauterine infection was diagnosed
according to criteria previously reported [9]: body tempera-
ture >38◦C, maternal tachycardia >100bpm, uterine tender-
ness, odor discharge, and leukocytosis >15,000/microliter.
2.1. Study Protocol and Treatment. Since magnesium sulfate
is to be used for second-line tocolysis when a betamimetic
agonist is not suﬃcient to reduce uterine contractions, all
women received a ﬁrst-line treatment (ritodrine) before
the start of magnesium sulfate. Ritodrine infusion was
titrated in the decided manner with a starting dose of 50
micrograms/min and an increment of 50 micrograms/min
over30to60minutes, untilthemaximumdoseof200micro-
grams/min. When uterine contractions were intractable by
its maximal dose, magnesium sulfate was given.
We applied a simple 2-arm protocol to add the magne-
sium sulfate infusion (Figure 1). One arm is to discontinue
ritodrine and change into magnesium sulfate with a loading
dose of 4gm over 30 minutes followed by a maintenance
doseof1.0-2.0gm/hr(magnesiumalone),which was titrated
as uterine contractions changed. When uterine contraction
increased by magnesium alone, attending physicians could
resume ritodrine at discretion. The other arm is to continue
ritodrine and add magnesium sulfate with a maintenance
dose of 1.0-2.0gm/hr (combination). Both drugs were given
with separate infusion pumps, and the total volume of
intravenous infusion was limited to <1,000mL per day. We
did not haveotherprotocolarms such asplacebo orno treat-
ment, because these treatments were considered unethical
by our ethics committee for women having intractable
uterine contractions even with the maximum dose of
ritodrine. After 48 hours of the allocated treatments, the
physicians chose either to stop or to continue tocolysis until
delivery.
2.2. Sample Size. Previous retrospective reports showed
that 60–90% of women given the combined treatment of
magnesium sulfate and ritodrine experienced a prolonged
pregnancy for ≥48 hours [3–7]. Thus, we assumed thatJournal of Pregnancy 3
Table 1: Maternal demographic and clinical characteristics at randomization.
Magnesium-alonegroup Combinationgroup Comparison
No. of pregnancies 14 19 —
Twin gestations 1 (7%) 4 (21%) NS
Maternal age (years) 31.3 ± 4.6 30.3 ± 4.8 NS
Nulliparous women 8 (57%) 8 (42%) NS
Prior preterm birth 1 (7%) 3 (16%) NS
Gestational age on admission(wk) 28.3 ± 4.4 27.2 ± 3.4 NS
Gestational age at start of ritodrine (wk) 28.1 ± 3.7 27.6 ± 3.2 NS
Gestational age at start of MgSO4 (wk) 29.3 ± 3.2 28.6 ± 3.4 NS
Cervical dilatation ≥3cm 0/14 0/19 NS
N S ;n o ts i g n i ﬁ c a n t .M g S O 4; magnesiumsulfate. Mean ± SD.
the inhibition rate to decrease uterine contraction using the
combination treatment was 20% in this study. Similarly, the
inhibition rate for magnesium alone was estimated as 45%.
When the eﬃcacy was compared using z-statistics with a
level of signiﬁcance of α = 0.05 (one-tailed) and a power
of 80%, the required number of women was calculated to be
42 women per group.
2.3. Randomization. We applied a block randomization
method. The block random size was arbitrarily chosen as 6,
which mathematically requires 14 institutions. Among the
14 institutions, 7 were designed to start magnesium alone
for the ﬁrst 3 women, followed by the combination therapy
for the next 3 women. The remaining 7 institutions were to
conduct treatments in the reverse manner.
As mentioned above, all the 14 institutions had the
same inclusion criteria for preterm labor and the same
treatment protocol for the ﬁrst-line tocolysis. Similarly,
Cesarean delivery was basically chosen for premature breech,
nonvertex twins, and previous cesarean birth, and antenatal
steroid was administered only once when delivery was
impending.
2.4. Evaluation. The number of uterine contractions was
assessed by cardiotocogram 48 hours after initiation of
magnesium sulfate. Treatment was deﬁned as eﬀective if
uterine contractions were reduced by more than 30% in
frequency compared to those occurring during the last
2 hours before magnesium sulfate infusion. Treatment
w a sd e ﬁ n e da si n e ﬀective if uterine contractions were not
reduced by 30%, labor progressed with apparent changes
in cervical ﬁndings, or the attending physician resumed
ritodrine in the magnesium-alone group due to insuﬃcient
tocolytic eﬃcacy. For the intention-to-treat analysis, women
who needed to deliver before 48 hours of observation due
to some complications other than preterm labor were also
classiﬁed as ineﬀective.
2.5. Statistics. Entry characteristics and outcome variables
were analyzed using the Mann-Whitney U test, the unpaired
t-test, and chi-square analysis with the Fisher exact test.
Multiple logistic regression analysis was performed to obtain
relative risk (RR) and the 95% conﬁdence interval (95% CI)
for the combination treatment, where an eﬀective treatment
was assigned the value 1 and an ineﬀective treatment the
value 0. P values <.05 are considered statistically signiﬁcant.
Data are expressed as mean ± standard deviation.
3.Resultsand Discussion
After 2 years of data collection, we had 45 eligible women
(Figure 1), but 12 women were excluded because they failed
to meet the inclusion criteria of preterm labor (n = 11),
and one was excluded due to monochorionic twin. The
remaining 33 women remained for analysis, which was less
than the required sample size (n = 84). Our control center
decided to extend the study period for 6 months, but no
further eligible case was enrolled. Thus, we decided to quit
sample collection and to perform analyses to determine if
there were some signiﬁcant results.
Maternal demographic and clinical characteristics at
randomization were similar between the 2 groups (Table 1)
regarding maternal age, parity, gestational age at admission,
and incidence of prior preterm birth. Dilatation of the
uterine cervix was less than 3cm in all women.
Timing of magnesium sulfate infusion varied from <24
hours to 30 days after commencing ritodrine tocolysis. The
prevalence of women who required second-line magnesium
treatment within 24 hours of ritodrine tocolysis was 12%
(4/33) in total, 7% (1/14) for magnesium alone, and 16%
(3/19) for the combination treatment (not signiﬁcant, Fisher
test).
Obstetric characteristics were also not statistically dif-
ferent (Table 2). Delivery rate <48 hours of the allocated
treatment was not signiﬁcantly diﬀerent between the 2
groups. Similarly, delivery week and cesarean delivery rate
were not signiﬁcantly diﬀerent.
The changes in uterine contractions during the ﬁrst 48
hours of magnesium infusion are depicted in Figure 2.T h e
number of uterine contractions decreased as the duration
of magnesium sulfate treatment increased. One woman
in each group progressed and delivered vaginally within
12 hours, and thus treatment for these women was classi-
ﬁed as ineﬀective. In the magnesium-alone group, uterine
contractions didnot decrease in5 women, who subsequently
requiredritodrinesupplementationduringtheﬁrst48hours.4 Journal of Pregnancy
Table 2: Obstetric characteristics at the start of the allocated treatment.
Magnesium-alone group (n = 14) Combination group (n = 19) Comparison
Delivery <48 hours after MgSO4 infusion 2/14 (14%) 1/19 (5%) NS
Delivery week (wk) 35.5 ± 2.2 32.8 ± 4.6 NS
Cesarean delivery (%) 8/14 (57%) 9/19 (47%) NS
NS; not signiﬁcant. Mean SD. Comparisons were performed by Fisher test or unpaired t-test.
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Figure 2: Temporal changes in uterine contractions after the start of magnesium sulfate treatment in the magnesium-alone group (a) and
combination group (b). The dotted lines in the magnesium-alone group represent those who required reinfusion of ritodrine to inhibit
uterine contraction. Asterisks represent those who delivered within 48 hours of magnesium infusion.
Table 3: Changes in uterine contractions at 48 hours after mag-
nesium sulfate infusion.
Magnesium-alone
group (n = 14)
Combination group
(n = 19)
Decreased 7 (50%) 18 (95%)
Unchanged ∼ Increased 7 (50%) 1∗ (5%)
∗P<. 01, Fisher test.
These 5 cases were also classiﬁed as ineﬀective. In the
magnesium-alone group, another women delivered before
48 hours because of massive genital bleeding of unknown
causes,which occurredafter12hoursofmagnesiuminfusion
without improvement of uterine contractions. This case was
also classed as ineﬀective.
Intention-to-treat analysis showed that the combination
treatment signiﬁcantly decreased the prevalence of ineﬀec-
tiveness compared to magnesium-alone treatment (Table 3,
P<. 01 by Fisher test, RR; 0.06, 95% CI 0.006 to 0.54 by
logistic regression analysis). In otherwords, the combination
treatment is 15-fold more eﬀective in inhibiting uterine
contractions than magnesium alone.
There were no serious maternal side eﬀects such as pul-
monary edema, respiratory complications, ileus-like symp-
toms, or rhabdomyolysis in both groups. Two women felt
mild and transient muscle weakness within 48 hours of
magnesium infusion (one for each treatment group), which
resolved spontaneously.
At 48 hours of the allocated treatment, all physicians
chosetocontinuetocolysisuntildelivery.Neonataloutcomes
for both groups are listed in Table 4.A l li n f a n t ss u r v i v e d
and did not suﬀer from neurological damage at 1 year of
age or older. There was no signiﬁcant diﬀerence in birth
weight, gestational weeks at delivery, prolongation time after
magnesium sulfate treatment, and incidence of low Apgar
score between the 2 groups.
In this randomized controlled trial, we found that 90%
of women (29/33) delayed their delivery for >48 hours after
magnesium sulfate infusion, when ritodrine alone failed
to inhibit uterine contractions. We also found that the
combination treatment was more eﬀective than magnesium
alone in decreasing uterine contractions.
Animal studies have shown that uterine activity is
initially inhibited by intravenous infusion of ritodrine for 6
hours, butactivity returnstothepreinfusion levelby 11to16
hours despite continuous infusion [10, 11]. Previous reports
based on in vitro experiments also showed that continuous
exposure ofmyometriumtobetamimeticagonistsresultedin
an initial myometrial relaxation followed by desensitization
and return of myometrial contractions [12–14]. In the
present study, 90% (30/33) of women received magnesium
sulfate after 24 hours of ritodrine infusion, suggesting that
they became desensitized and uterine contractions resumed,
which was inhibited by administering magnesium sulfate.
Betamimetic agonists, on binding with beta-2 recep-
tors on the cell membrane, activate adenlylate cyclase to
increase the intracellular concentration of cyclic adenosine
monophosphate, resulting in decreased availability of free
intracellular calcium for actin and myosin, leading to
relaxation of uterine smooth muscle. On the other hand,
magnesium sulfate acts on the voltage-dependent calcium
channels to competitively block the calcium inﬂux, leading
to the inhibition of calcium-dependent myosin light-chain
kinase phosphorylation. It is logical to speculate that there
ma ybesomeadditi v eeﬀectsthat inhibit uterinecontractionsJournal of Pregnancy 5
Table 4: Neonatal outcomes of magnesium alone and combinationgroups.
MgSO4 therapy group Combined therapy group Comparison
Number of infants 15 23 —
Birth weight (gm) (range) 2378 ± 478 (1704–3656) 1912 ± 681 (488–2876) NS
Gestational age (wk) (range) 35.5 ± 2.2 (32–41) 32.8 ± 4.6 (24–38) NS
Prolongationafter magnesium sulfate therapy (days) 41.5 ± 32.3 (0–108) 27.8 ± 22.3 (2–59) NS
Apgar score at 5min (<6) 0/15 1∗/23 NS
∗Neonate delivered at 24 weeks gestations (birth weight 488gm with Apgar score 2/5 (1min/5min)).
NS, not signiﬁcant by unpaired t-test, Mann-Whitney U test, or Fisher test.
since both agents have diﬀerent mechanisms of action.
Historically, the combination therapy may [4–7]o rm a yn o t
[8] improve tocolytic eﬃcacy. Our results agreed with that a
combination treatment is superior to magnesium alone in
prolonging pregnancy, even in the stage of desensitization
during ritodrine treatment.
We used magnesium sulfate for the second-line tocolysis
when the betamimetic eﬀe c tw a sn o ts u ﬃcient to reduce
uterine contractions. This situation is unique because the
fact that a betamimetic agonist alone failed to inhibit uterine
contractions suggests that the situation is more likely to
occur in true labor than false labor, and the placebo eﬀect
may not interfere with the results. Under these conditions,
the adjunctive use of magnesium sulfate with ritodrine is 15-
fold more eﬀective in inhibiting uterine contractions than
magnesium sulfate alone.
This study has several advantages. One is its nature
of a randomized controlled trial. Another is the above-
mentioned study protocol where the placebo eﬀect is taken
into consideration. This study also has some limitations.
The major problem is its underpowered number and uneven
allocation due to incomplete blockrandomization. Only 3 of
the 14 institutions fulﬁlled the allocated number (n = 6) of
data collection, 3 ﬁnished the ﬁrst allocated block (n = 3)
with the second block halfway, and 2 institution did not
enroll any women. The control center strongly requested for
enrollment and extended the study period for 6 months,
but no cases were added. Therefore, only 45 women were
included, which is much smaller than the required number.
Even with this major limitation, our conclusion is of clinical
importance that combination of magnesium with ritodrine
is 15-fold more eﬀective to inhibit uterine contractions than
magnesium alone, in which ritodrine alone is not suﬃcient
to inhibit them.
4.Conclusions
This randomized trial revealed that adjuvant magnesium
with ritodrine signiﬁcantly reduced uterine contractions
than magnesium alone, when uterine contractions are in-
tractable with ritodrine infusion.
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